Development of an Anti-Bleeding Agent for Recombinant Hirudin Induced Skin Bleeding in the Pig

Summary

Recombinant hirudin (rH) is a highly specific thrombin inhibitor which is under clinical investigation for various thrombotic disorders. However, one of its potential risks during clinical use might be hemorrhage, especially when combined with other agents interfering with the coagulation system like antiplatelet or fibrinolytic agents. In this experimental study we investigated whether Haemate, a von Willebrand Factor (vWF) and factor VIII containing product, could correct rH/aspirin induced bleeding in an experimental pig study. Skin bleeding time was evaluated in three open, placebo-controlled, randomized studies following comparable designs. A total of 62 animals were given a short-term infusion of aspirin (20 mg/kg) followed by a three-hour infusion of a high or low dose (0.3 or 0.5 mg/kg/h) of rH. At cessation of rH infusion, animals were allocated to treatment with either Haemate (30 FVIII U/kg) or the recombinant factor VIII, Helixate, which is devoid of vWF. The skin bleeding time (SBT, given as times of baseline) as measured four hours after the start of the rH infusion was defined as the prospective endpoint.

In study 1 (low dose rH + Haemate) 4 h SBT was 2.18 (placebo) and 1.61 (Haemate, p = 0.0111). In study No. 2 (high dose rH + Haemate) SBT was 2.58 in placebo and 1.73 in Haemate (p = 0.0001). No significant difference between placebo and treatment were detected in study No. 3 (low dose rH + Helixate). Haemate but not Helixate significantly decreased bleeding time as compared to placebo at termination of the study (7 hours) which was defined as the secondary endpoint. No effect on either aPTT nor rH plasma levels were observed with any of the study drugs. It was concluded that Haemate decreases excess bleeding induced by rH/aspirin treatment without altering rH’s anticoagulant effect.

• References

• 1 Johnson PH. Hirudin: Clinical potential of a thrombin inhibitor. Annu Rev Med 1994; 45: 165-77.
• 2 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe-Seyler’s Z Physiol Chem 1957; 308: 147-56.
• 3 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-8.
• 4 Dickneite G, Czech J. Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumonia sepsis. Thromb Haemost 1994; 71: 6768-72.
• 5 Agnelli G, Renga C, Weitz JI, Nence GG, Hirsh J. Sustained antithrombotic activity of hirudin after its plasma clearance: Comparison with heparin. Blood 1992; 80: 960-5.
• 6 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
• 7 Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81-8.
• 8 Schiele F, Vuillemenot P, Kramarz JK, Anguenot T, Bernard Y, Bassand YP. Use of recombinant hirudin as antithrombotic treatment in patients with heparin-induced thrombocytopenia. Am J Hematol 1995; 50: 20-5.
• 9 Fox KAA. r-Hirudin in unstable angina pectoris. Rationale and preliminary data from the APT pilot study. Eur Heart J 1995; 16: 28-32.
• 10 Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry PC. Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 1994; 72 (02) 227-41.
• 11 Bridey F, Dreyfus M, Parent F, Bros A, Fischer AM, Camez A, Simonneau G, Duroux P, Meyer D. Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism. Am J Hematol 1995; 49: 67-72.
• 12 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.. Randomised trial of intravenous streptokinase, oral, aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-60.
• 13 Cannon CP, McCabe CH, Henry TD, Schweiger MM, Gibson RS, Müller HS, Becker R, Kleiman NS, Haugland M, Anderson JL, Sharaf BL, Edwards SJ, Rogers WJ, Williams DO, Braunwald E. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 5 Trial. JACC 1994; 5: 993-1003.
• 14 Antman ES. and the TIMI 9A Investigators. Hirudin in acute myocardial infarction: Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
• 15 Neuhaus KL, Essen RV, Tebbe U, Jessel A, Heinrichs H, Mäurer W, Döring W, Harmjanz D, Kötter V, Kahlhammer E, Simon H, Horacek T. Safety observations from the pilot phase of the randomized rH for improvement for thrombolysis (HIT-III) study. Circulation 1994; 90: 1638-42.
• 16 Zeymer U, and Neuhaus KL. Hirudin and excess bleeding. Drug Safety 1995; 12: 234-9.
• 17 Butler KD, Dolan SL, Talbot MD, Wallis RB. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat. Blood Coag Fibrinol 1993; 4: 459-64.
• 18 Bove CM, Casey B, Marder VJ. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost 1996; 75 (03) 471-5.
• 19 Diehl KH, Römisch J, Hein B, Jessel A, Ronneberger H, Pâques EP. Investigation of activated prothrombin complex concentrate as potential hirudin antidote in animal models. Haemostasis 1995; 25: 182-92.
• 20 Irami MS, Harvey JW, Sexon RG. Reversal of hirudin-induced bleeding diathesis by prothrombin complex concentrate. Am J Cardiol 1995; 75: 422-3.
• 21 Dickneite G, Friesen HJ, Kumpe G, Reers M. Reduction of rH induced bleeding in pigs by the administration of von Willebrand Factor. Platelets 1996; 7: 283-90.
• 22 Lyons SE, Ginsbury E. Molecular and cellular biology of von Willebrand Factor. T Cardiovasc Med 1994; 4: 34-9.
• 23 Altman R, Rouvier J, Gurfinkel E. Oral anticoagulant treatment with and without aspirin. Thromb Haemost 1995; 74: 506-10.
• 24 Desu MM, Raghavarao D. Sample size methodology. Academic Press Inc; San Diego: 1990: 23-34.
• 25 Rao CR. Linear statistical inference and its applications. 2nd edition. John Wiley & Sons; New York: 1973: 236-44.
• 26 Breddin HK, Radziwon P, Eschenfelder V, Müller-Peltzer H, Esslinger HU. PEG-hirudin and acetylsalicylic acid show a strong interaction on bleeding time. Ann Hematol 1996; 72: 214.
• 27 Nowak G. Pharmacokinetics of hirudin. Semin Thromb Hemost 1991; 17: 145-9.
• 28 Nowak G, Bucha E, Gööck Th, Thieler H, Markwardt F. Pharmacology of r-Hirudin in renal impairement. Thromb Res 1992; 66: 707-15.
• 29 Meyer BH, Luus HG, Müller FO, Badenhorst PN, Röthig HJ. The pharmacology of recombinant hirudin, a new anticoagulant. S Afr Med J 1990; 78: 268-70.
• 30 Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, Silling-Engelhardt G, Close P. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993; 22: 364-72.
• 31 Zoldhelyi P, Webster WI, FRACP ChB, Fuster V, Grill D, Gaspar DLPN, Edwards SJ, Cabot CF, Chesebro JH. Recombinant hirudin in patients with chronic, stable coronary artery disease safety, half-life, and effect on coagulation parameters. Circulation 1993; 88: 2015-22.
• 32 Cardot JM, Lefèvre GY, Godbillon JA. Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration. J Pharmacokin Biopharm 1994; 22: 147-56.
• 33 Kobrinsky NJ Gerrard, Israels E, Cheang MS, Watson CM, Bishop A, Schroeder ML. Shortening of bleeding time by 1-deamino-8-arginine vasopressin in various bleeding disorders. Lancet 1994; 2: 1145-8.
• 34 Pötzsch B, Riess FC, Madlener K, Völpel H, Müller-Berghaus G, Greinacher A. Recombinant hirudin as anticoagulant during cardio-pulmonary bypass surgery. Ann Hematol 1997; 74: 153.
• 35 Auerswald G, Anders O, Keller F, Kemkes-Matthes B, Krelbich U, Leithaeuser H, Marx G, Scheel H, Schott G, Voss R, Wankmüller H. Clinical study of the biological efficacy of a high purity FVIII:C-vWF complex concentrate in patients with von Willebrand disease. Ann Hematol 1997; 70.
• 36 Hennekens CH, O’Donnell CJ, Ridker PM. Current and future perspectives on antithrombotic therapy of acute mycocardial infarction. Eur Heart J 1995; 16: 2-9.
• 37 Murdock PJ, Woodhams BJ, Matthews KB, Pasi KJ, Goodall AH. von Willebrand Factor activity detected in a monoclonal antibody-based ELISA: An alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997; 78: 1272-7.